Comments on current guidelines of type 2 diabetes mellitus treatment

Česká verzia

Authors: Emil Martinka
Authors place of work: Národný endokrinologický a diabetologický ústav, n. o., Ľubochňa, Slovenská republika
Published in the journal: Vnitř Lék 2017; 63(3): 211-217
Category: Guidelines

Summary

In an effort to facilitate the widest possible application of recent findings in diabetology and the related medical fields, with regard to characteristics of medicines and current possibilities of using modern procedures, but also to their limitations due to the financial capacities of health insurance companies, SDS innovates its therapeutic recommendations for the treatment of diabetes mellitus on a regular basis. The most recent recommendations were issued by SDS in August 2016. The review discusses and describes several factors which the authors considered during their preparation: (1) Compliance with the findings of evidence-based medicine, compliance with reference recommendations (therapeutic recommendations ADA/EASD), compliance with summary characteristics of active substances in the treatment of diabetes mellitus and approved possibilities of their use, and compliance with indicative restrictions (IO) which define medical and economic conditions for health insurance covered treatment. (2) Certain departure from the “glucocentric” approach to therapy, in favour of the approach preferring the selection of drugs based on clinical characteristics of the patient and proven benefits/risks of individual drugs (3) Preference of groups as well as individual active substances within groups based on evidence medicine regarding the individual active substances for specific patient groups. (4) Emphasis on individualization of goals for glycemic control (5) Emphasis on the right classification of diabetes mellitus as the basic condition for the selection of an optimum therapeutic procedure, and (6) Emphasis on education and overcoming of clinical inertia, and patient medication adherence and medication “literacy” as the basic condition for successful therapy. The discussion also considers the outcomes of the most recent studies including of the studies focusing on empagliflozin and liraglutide, as well as recent modifications of the therapeutic recommendations of the American and Canadian Diabetes Association.

Key words:
type 2 diabetes mellitus – therapeutic recommendations – algorithm – empagliflozin – liraglutide

Zdroje

1. American Diabetes Assocation. Standards of medical care in diabetes – 2017. Summary of revisions. Diabetes Care 2017; 40(Suppl 1): S4-S5.

2. Buse J. LEADER Investigator Raises ‚Exciting Question‘ Medscape. Jun 17, 2016. Dostupné z WWW: http://www.medscape.com/viewarticle/864870.

3. Gerstein HC, Miller ME, Byington RP et al. [The Action to Control Cardiovascular Risk in Diabetes Study Group]. Effect of intensive glucose lowering in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2545–2559. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0802743>.

4. Patel A, MacMahon S, Chalmers J et al. [The ADVANCE Collaborative Group]. Intensive Blood Glucose Control and VascularOutcomes in Patients with Type 2 Diabetes N Engl J Med 2008; 358(24): 2560–2572. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0802987>.

5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I. Diagnosis and classifiction of diabetes mellitus – Provisional report of WHO consultation. Diabetic Medicine 1998; 15(7): 539–553.

6. Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.b4909>.

7. [Canadian Diabetes Association Clinical Practice Guidelines Expert Committee]. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Can J Diabetes 2016; 40(3): 193–195. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcjd.2016.02.006>.

8. Dormandy JA, Charbonnel B, Eckland DJA et al. [PROactive investigators]. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–1289.

9. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). 2016. Dostupné z WWW: http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm.

10. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Update 2016. Dostupné z WWW: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM493965.pdf.

11. Farmer AJ, Rodgers LR, Lonergan M et al. Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care 2016; 39(2): 258–263. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–1194>.

12. Ferranini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016; 39(7): 1108–1114. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–0330>.

13. Green JB, Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373(3): 232–242. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1501352>.

14. Holman RR, Paul SK, Bethel MA al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577–1589. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0806470>.

15. Cherney D et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129(5): 587–597. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005081>.

16. Inzucchi ES, Bergenstal RM, Buse JB et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1): 140–149. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14–2441>.

17. Marso, SP, Daniels GH, Brown-Frandsen K et al. for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.

18. Marso, SP, Bain, SC, Consoli, A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375(19):1834–1844. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607141>.

19. Martinka, E, Rončáková M, Mišániková M et al. Autoimmune insulitis in patients with type 2 diabetes mellitus A randomized clinical trial in hospitalized patients. Vnitř Lék 2016; 62(7–8): 521–533.

20. Martinka E, Mišániková M. Iatrogénna hypoglykémia ako závažný medicínsky problém. Interná Med 2016; 16(4): 135–142.

21. Martinka E., Uličiansky V, Mokáň M et al. Konsenzuálny terapeutický algoritmus pre diabetes mellitus 2. typu (v súlade s SPC, aktuálnym znením indikačných obmedzení a odporúčaní ADA/EASD). Stav k 31. 8. 2016 v spolupráci s členmi Výboru slovenskej diabetologickej spoločnosti. Interná Med 2016; 16(7–8): 1-x.

22. McCall B. More LEADER: Liraglutide Delays Progression of Renal Events. Medscape. Sep 20, 2016. Dostupné z WWW: http://www.medscape.com/viewarticle/868994.

23. MZSR. Aktuálne znenie indikačných obmedzení pre preskripciu liekov hradených z verejného poistenia. Dostupné z WWW: http://www.health.gov.sk/Clanok?lieky201605.

24. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32(1): 84–90. Dostupné z DOI: <http://dx.doi.org/10.2337/dc08–1355.>.

25. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457–2471.

26. Schernthaner G, Curie CJ, Schernthaner GH. Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013. Diabets Care 2013; 36(Suppl 2): S155-S161. Dostupné z DOI: <http://dx.doi.org/10.2337/dcS13–2031>.

27. Schramm TK, Gislason GH, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32(15): 1900–1908. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr077>.

28. Sonesson C, Johansson PA, Johnsson E et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta -analysis. Cardiovasc Diabetol 2016; 15:37. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–016–0356-y>.

29. Tucker ME. ‚New Era‘ of Type 2 Diabetes Treatment as LEADER Unveiled? Medscape. Jun 13, 2016. Dostupné z WWW: http://www.medscape.com/viewarticle/864729.

30. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323–334. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1515920>.

31. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

32. Zoungas S, Chalmers J, Neal B. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med 2014; 371(15): 1392–1406. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1407963>.